home / stock / meip / meip quote
Last: | $3.26 |
---|---|
Change Percent: | -1.43% |
Open: | $3.38 |
Close: | $3.26 |
High: | $3.45 |
Low: | $3.22 |
Volume: | 7,394 |
Last Trade Date Time: | 04/24/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$3.26 | $3.38 | $3.26 | $3.45 | $3.22 | 7,394 | 04-24-2024 |
$3.3323 | $3.33 | $3.3323 | $3.3323 | $3.2401 | 5,008 | 04-23-2024 |
$3.37 | $3.22 | $3.37 | $3.37 | $3.22 | 6,549 | 04-22-2024 |
$3.25 | $3.275 | $3.25 | $3.3 | $3.22 | 26,402 | 04-19-2024 |
$3.25 | $3.31 | $3.25 | $3.38 | $3.25 | 12,047 | 04-18-2024 |
$3.31 | $3.25 | $3.31 | $3.44 | $3.2 | 9,086 | 04-17-2024 |
$3.2 | $3.27 | $3.2 | $3.4433 | $3.2 | 16,466 | 04-16-2024 |
$3.25 | $3.34 | $3.25 | $3.36 | $3.23 | 13,289 | 04-15-2024 |
$3.27 | $3.79 | $3.27 | $3.79 | $3.21 | 22,242 | 04-12-2024 |
$3.63 | $3.77 | $3.63 | $3.8343 | $3.61 | 35,872 | 04-11-2024 |
$3.76 | $3.82 | $3.76 | $3.84 | $3.7501 | 15,789 | 04-10-2024 |
$3.82 | $3.795 | $3.82 | $3.88 | $3.795 | 10,894 | 04-09-2024 |
$3.83 | $3.78 | $3.83 | $3.875 | $3.7124 | 16,398 | 04-08-2024 |
$3.75 | $3.87 | $3.75 | $3.87 | $3.75 | 10,469 | 04-05-2024 |
$3.95 | $4.01 | $3.95 | $4.06 | $3.8 | 15,662 | 04-04-2024 |
$4.05 | $4.02 | $4.05 | $4.0651 | $3.85 | 25,338 | 04-03-2024 |
$4 | $3.85 | $4 | $4.1099 | $3.839 | 31,958 | 04-02-2024 |
$3.8841 | $4 | $3.8841 | $4 | $3.85 | 52,886 | 04-01-2024 |
$4 | $3.92 | $4 | $4.1473 | $3.8113 | 13,334 | 03-29-2024 |
$4 | $3.92 | $4 | $4.1473 | $3.8113 | 13,334 | 03-28-2024 |
News, Short Squeeze, Breakout and More Instantly...
– MEI Pharma Board Unanimously Determines, Based on Clinical Data Results, Not to Proceed with Second Capital Return Under 2023 Anson and Cable Car Cooperation Agreement: Conserving Capital, Prioritizing Measured Investment, Extending Operational Runway – MEI Pharma, Inc. ...
– Cohort 1 Exceeds Predetermined Non-Progression Threshold in the Ongoing Phase 1b Study – – ME-344 in Combination with Bevacizumab was Generally Well-tolerated with no Evidence of Overlapping Toxicity – – MEI to Continue Advancing ME-344 via Dev...
MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today announced that David Urso, president and chief executive officer of MEI Pharma, will participate in a firesi...